Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Response-guided hcv therapy

A therapy and dosage form technology, applied in the field of providing response-guided HCV therapy, can solve problems such as high cost and difficulty in patient compliance

Inactive Publication Date: 2018-08-31
EMORY UNIVERSITY
View PDF37 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The cost of these treatments is prohibitive and patient compliance is difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Response-guided hcv therapy
  • Response-guided hcv therapy
  • Response-guided hcv therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0184] Example 1: Efficacy and Safety of a 3-Week Response-Guided Triple Direct-Acting Antiviral Therapy Against Chronic Hepatitis C Infection: A Phase 2, Open-Label, Proof-of-Concept Study

[0185] Overview:

[0186] DAA has a high cure rate and is well tolerated in patients with hepatitis C virus (HCV) infection. However, a shorter course of treatment may improve adherence, affordability, and increase DAA accessibility. We speculated that adding an NS3 protease inhibitor to the NS5A-NS5B (nucleoside) dual inhibitor could improve antiviral efficacy in individuals with rapid virological response (RVR) and shorten the duration of treatment to 3 weeks (wks), The rapid virological response (RVR) was defined as plasma HCV RNA <500 IU / ml on the second day. Therefore, the aim of this study was to examine the antiviral efficacy and safety of a 3-week response-guided therapy with an NS3 protease inhibitor and a dual NS5A inhibitor-NS5B nucleotide (HCV) infection with a course of di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to solid dosage forms comprising anti-HCV compounds and methods of using such dosage forms to treat or prevent HCV infection. Direct-acting antiviral agents (DAAs) havea high cure rate, and favorable tolerability in persons infected with hepatitis C virus (HCV). However, shorter courses of therapy can improve adherence, affordability, and increase DAAs accessibility. The addition of an NS3 protease inhibitor to dual NS5A-NS5B (nucleoside) inhibitors enhances antiviral efficacy, and reduces treatment duration to 3 weeks (wks) in individuals with a rapid virologicresponse (RVR), defined as plasma HCV RNA<500, or < 1,000, IU / mL by Day 2 of treatment.

Description

technical field [0001] The present disclosure relates to formulations comprising three or more active specific anti-HCV compounds for use in combination therapy, methods of using the formulations to treat, cure or prevent HCV infection, and methods of providing response-directed HCV therapy. Background technique [0002] Recent estimates put the number of people infected with hepatitis C virus (HCV) at more than 170 million worldwide, including 3 million in the United States. The infection rate is approximately 4 to 5 times that of the human immunodeficiency virus (HIV). While in some individuals the innate immune response is able to overcome the virus, in most cases a chronic infection is established leading to an increased risk of developing cirrhosis and hepatocellular carcinoma. [0003] The virus causing HCV infection is a positive-strand RNA virus belonging to the Flaviviridae family. The HCV genome encodes a polyprotein that is cleaved into ten individual proteins, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7072A61K31/4178A61K31/4184A61K31/4709A61P31/14
CPCA61K31/4178A61K45/06A61K31/4725A61K31/439A61K31/7072A61P31/14A61K31/4184A61K31/4709A61K31/519A61K2300/00G01N33/56983G01N2800/52
Inventor 雷蒙德·F·斯基那兹
Owner EMORY UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com